Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MGAM | O43451 | 1/20 | 0.58 |
| ▸ | SI | P14410 | 1/20 | 0.58 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malonic Acid Diethyl Ester SCHEMBL7792998 | 0.96 | GAA (0.60) | GAAMGAMSIMGAM2ALDH1A1 | |
| Potassium Ion SCHEMBL7793002 | 0.89 | GAA (0.47) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL28009465 | 0.84 | GAA (0.61) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10185937 | 0.83 | GAA (0.58) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL182126 | 0.82 | GAA (0.64) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL28885358 | 0.82 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL2576619 | 0.81 | GAA (0.56) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL27842787 | 0.81 | GAA (0.56) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10595482 | 0.81 | GAA (0.56) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL28825664 | 0.80 | GAA (0.61) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118405976-A | Synthesis method of fluoro propionyl ethyl acetate | 张克珍 | 2024-07-30 | — | — | CN | disclosed |
| CN-118307408-A | Preparation method of ethyl 2-fluoropropionylacetate | 上海恩氟佳科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-107987024-B | Pyrimidine amine compound with biological activity and preparation method thereof | 湖南化工研究院有限公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-111217758-A | Preparation method of 6-ethyl-5-fluoro-4-chloropyrimidine | 湖南复瑞生物医药技术有限责任公司 | 2020-06-02 | — | — | CN | disclosed |
| CN-102939290-B | 2,3-dihydro-1H-indenes-1-base-2,7-diaza spiro [3.5] nonane derivatives and as the antagonist of growth hormone-releasing peptide acceptor or the purposes of inverse agonist | PFIZER INC. (US) | 2015-09-16 | — | — | CN | disclosed |
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | SMITHKLINE BEECHAM, PLC | 2005-10-27 | — | — | US | disclosed |
| EP-1228043-B1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2005-01-12 | — | — | EP | disclosed |
| US-6579871-B2 | Phenyl oxazoles or thiazoles | ELI LILLY AND COMPANY | 2003-06-17 | — | — | US | disclosed |
| EP-0971709-B1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | LILLY CO ELI (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030050311-A1 | Methods of using novel compounds as neuro-protective agents | PANETTA JILL ANN (US) | 2003-03-13 | — | — | US | disclosed |
| WO-1999009979-A1 | METHOD FOR TREATING NEUROPATHIC PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999009829-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999009980-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998015274-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
| US-5260285-A | Substituted imidazopyridazines as angiotensin II antagonists | MERCK & CO., INC. (US) | 1993-11-09 | — | — | US | disclosed |
| US-5250521-A | Administering in treatment of eleuated blood pressure, conjestive heart failure and ocular hypertension | MERCK & CO., INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0490587-A1 | Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin II antagonists | MERCK & CO. INC. (US) | 1992-06-17 | — | — | EP | disclosed |
| EP-0168950-B1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-01-11 | — | — | EP | disclosed |
| US-4769386-A | Imidazolylthioalkenoic acids and -alkenols and leukotriene antagonistic composition containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0168950-A1 | Leukotriene antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1986-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | HTR1B, HTR1A, HTR1D | GAA 2898/4885MGAM 4433/4885SI 2327/4885 |
| US-20030050311-A1 | Methods of using novel compounds as neuro-protective agents | NLN, GAP43, TXN2 | GAA 3203/4885MGAM 4580/4885SI 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.